Screener
CapEx at other companies
Other financials
Where this comes from
Reported directly by Monte Rosa Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The source filing: Monte Rosa Therapeutics, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:09 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-336711
| (in thousands) | Six months ended June 30, 2026 | Six months ended June 30, 2025 |
|---|---|---|
| Deferred revenue | (13,177) | (106,910) |
| Net cash used in operating activities | $(81,483) | $(80,212) |
| Cash flows from investing activities: | ||
| Purchases of property and equipment | (6,591) | (3,282) |
| Purchases of marketable securities | (408,071) | (157,047) |
| Proceeds from maturities of marketable securities | 124,805 | 85,424 |
| Net cash used in investing activities | $(289,857) | $(74,905) |
| Cash flows from financing activities: |
Item 1. Financial Statements
FAQ
- What is Monte Rosa Therapeutics, Inc.'s capex?
- Monte Rosa Therapeutics, Inc. (GLUE) reported capex of $4.72M in Q2 2026.
- How has Monte Rosa Therapeutics, Inc.'s capex changed year-over-year?
- Monte Rosa Therapeutics, Inc.'s capex increased by 178.6% year-over-year, from $1.7M to $4.72M.
- What is the long-term trend for Monte Rosa Therapeutics, Inc.'s capex?
- Over 4 years (2021 to 2025), Monte Rosa Therapeutics, Inc.'s capex has grown at a -16.6% compound annual growth rate (CAGR), from $9.73M to $4.7M.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about Monte Rosa Therapeutics, Inc.'s capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude